These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11501548)

  • 21. Losartan and severe migraine.
    Ahmad S
    JAMA; 1995 Oct; 274(16):1266-7. PubMed ID: 7563525
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible ageusia associated with losartan.
    Schlienger RG; Saxer M; Haefeli WE
    Lancet; 1996 Feb; 347(8999):471-2. PubMed ID: 8618505
    [No Abstract]   [Full Text] [Related]  

  • 24. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug points: prolonged cholestasis associated with irbesartan.
    Hariraj R; Stoner E; Jader S; Preston DM
    BMJ; 2000 Sep; 321(7260):547. PubMed ID: 10968816
    [No Abstract]   [Full Text] [Related]  

  • 26. Lichenoid drug eruption due to an antihypertonic drug containing irbesartan and hydrochlorothiazide.
    Pfab F; Athanasiadis GI; Kollmar A; Ring J; Ollert M
    Allergy; 2006 Jun; 61(6):786-7. PubMed ID: 16677251
    [No Abstract]   [Full Text] [Related]  

  • 27. Anaemia in dialysis patients as a side-effect of sartanes.
    Schwarzbeck A; Wittenmeier KW; Hällfritzsch U
    Lancet; 1998 Jul; 352(9124):286. PubMed ID: 9690412
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ
    J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    Bold KO
    MMW Fortschr Med; 2001 May; 143(22):12-3. PubMed ID: 11460392
    [No Abstract]   [Full Text] [Related]  

  • 30. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis.
    Navalkar S; Parthasarathy S; Santanam N; Khan BV
    J Am Coll Cardiol; 2001 Feb; 37(2):440-4. PubMed ID: 11216960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute renal failure after administration of losartan.
    Lamb RV; Walton T
    W V Med J; 1996; 92(5):241. PubMed ID: 8918197
    [No Abstract]   [Full Text] [Related]  

  • 32. Commentary: do angiotensin II receptor antagonists regress left ventricular hypertrophy?
    Lip GY
    J Hum Hypertens; 1996 Nov; 10(11):725-7. PubMed ID: 9004101
    [No Abstract]   [Full Text] [Related]  

  • 33. A look through the new therapeutic window: irbesartan.
    Waeber B; Brunner HR
    J Hypertens Suppl; 1998 Sep; 16(7):S11-6. PubMed ID: 9855026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
    Li S; Cao B; Feng QH; Li XZ
    Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marked hepatotoxicity associated with losartan treatment.
    Nygaard B; Strandgaard S
    Blood Press; 1996 May; 5(3):190-1. PubMed ID: 8790930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of long-term Irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study.
    Venon WD; Baronio M; Leone N; Rolfo E; Fadda M; Barletti C; Todros L; Saracco G; Rizzetto M
    J Hepatol; 2003 Apr; 38(4):455-60. PubMed ID: 12663237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
    Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K
    Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of age and gender on the pharmacokinetics of irbesartan.
    Vachharajani NN; Shyu WC; Smith RA; Greene DS
    Br J Clin Pharmacol; 1998 Dec; 46(6):611-3. PubMed ID: 9862252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.